锝[^(99)Tc]亚甲基二膦酸盐与DMARDs联用对类风湿关节炎患者的疗效评价  

Efficacy evaluation of technetium[^(99)Tc]methylene bisphosphonate combined with DMARDs in patients with rheumatoid arthritis

作　　者：马文涛 牛翠 张继超 Ma Wentao;Niu Cui;Zhang Jichao(Department of Nephropathy and Immunology,Rizhao Central Hospital,Rizhao 276800,China;Department of Thoracic Surgery,Rizhao Central Hospital,Rizhao 276800,China)

机构地区：[1]日照市中心医院肾病免疫科,山东日照276800 [2]日照市中心医院胸外科,山东日照276800

出　　处：《山东第一医科大学（山东省医学科学院）学报》2021年第12期913-916,共4页Journal of Shandong First Medical University ＆ Shandong Academy of Medical Sciences

摘　　要：目的分析锝[^(99)Tc]亚甲基二膦酸盐与传统慢作用抗风湿药物(DMARDs)联用对类风湿关节炎患者的疗效。方法选取我院2018年1月至2020年6月期间收治的80例类风湿关节炎患者,按随机双盲法分为两组,对照组(n=40)采用DMARDs治疗,观察组(n=40)采用锝[^(99)Tc]亚甲基二膦酸盐联合DMARDs治疗,比较两组临床疗效、血清炎症水平及28个关节疾病活动评分(DAS28评分)。结果观察组临床总有效率97.50%高于对照组的77.50%,差异有统计学意义(P<0.05).观察组患者治疗后DAS28评分低于对照组,ESR、CRP、IL-17水平低于对照组,差异有统计学意义(P<0.05);观察组不良反应发生率为5.00%,对照组发生率为10.00%,差异无统计学意义(P>0.05).结论锝[^(99)Tc]亚甲基二膦酸盐与传统慢作用抗风湿药物(DMARDs)联用,可提高类风湿关节炎患者的临床疗效,改善临床症状。Objective:To analyze the effect of technetium[^(99)Tc]methylene bisphosphonate combined with antirheumatic drugs(DMARDs)on the efficacy and DAS28 score of patients with rheumatoid arthritis.Methods:A total of 80 patients with rheumatoid arthritis admitted to our hospital from January 2018 to June 2020 were randomly divided into two groups by double-blind method.The control group(n=40)was treated with DMARDs.The observation group(n=40)was treated with technetium[^(99)Tc]methylene bisphosphonate combined with DMARDs;Clinical efficacy,serum inflammation and 28 joint disease activity scores(DAS28 score)were compared between the two groups.Results:The total effective rate of observation group was higher(97.50%)than that of control group(77.50%),the difference was statistically significant(P<0.05).After treatment,DAS28 score,ESR,GRP and IL-17 levels in observation group were lower than control group,and the differences were statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 5.00%,and the incidence in the control group was 10.00%,with no statistical significance(P>0.05).Conclusion:Technetium[^(99)Tc]methylene bisphosphonate combined with traditional slow acting anti rheumatic drugs(DMARDs)can improve the clinical efficacy and clinical symptoms of patients with rheumatoid arthritis,and it is worthy of application.

关 键 词：锝[^(99)Tc]亚甲基二膦酸盐 传统慢作用抗风湿药物(DMARDs) 类风湿关节炎 DAS28评分 

分 类 号：R593.2[医药卫生—内科学]